ArticleFrontiers in immunology2026
A compass in the challenge: the CALLY index as a prognostic biomarker in advanced cholangiocarcinoma treated with chemoimmunotherapy: a retrospective propensity score-matched cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic Value of the C-Reactive Protein-Albumin-Lymphocyte Index in Hepatobiliary and Pancreatic Cancers: A Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- The Evolving Landscape of Immune Regulation and Immunotherapy in Cholangiocarcinoma and Biliary Tract Cancer.Cancers · 2026Review
- The CALLY Index Is Associated with Overall Survival in Patients with De Novo Metastatic Gastric Adenocarcinoma.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The management of advanced cholangiocarcinoma (CCA) remains a clinical challenge. Prognostic biomarkers are needed to guide treatment decisions. The C-reactive protein-albumin-lymphocyte (CALLY) index reflects nutritional, immune, and inflammatory status and has shown prognostic value in other cancers. However, its role in CCA patients receiving chemoimmunotherapy is unexplored. Methods: We conducted a retrospective propensity score-matched (PSM) cohort study involving advanced CCA patients who were treated with chemoimmunotherapy. Participants were stratified into high- or low-CALLY groups based on an optimal cut-off value of 1.42. PSM (1:1) was applied to balance baseline covariates. Overall survival (OS) and progression-free survival (PFS) were compared between groups using Kaplan-Meier analysis, and Cox regression analysis was employed to identify prognostic factors. The prognostic models underwent comprehensive internal validation, including bootstrap resampling (1,000 iterations) for calibration and discrimination assessment. Health-related quality of life (HRQoL) was assessed using a mixed model for repeated measures. Results: After 1:1 propensity matching, 55 patients were retained in each group, with balanced baseline characteristics. The high-CALLY group exhibited significantly longer median OS (13.00 months vs. 11.50 months; P = 0.019) and PFS (7.50 months vs. 6.00 months; P = 0.020). Cox analysis confirmed the CALLY index as a valuable prognostic factor for both OS (hazard ratio (HR), 0.68; 95% confidence interval (CI), 0.50 to 0.93; P = 0.014) and PFS (HR, 0.70; 95% CI, 0.58 to 0.85; P < 0.001). Internal validation demonstrated good model performance, with optimism-corrected C-indices of 0.704 for OS and 0.716 for PFS. Furthermore, patients with a high CALLY index showed significantly slower deterioration in HRQoL from week 18 onward (P < 0.05). Conclusion: The CALLY index is a robust prognostic biomarker for advanced CCA patients undergoing chemoimmunotherapy, associated with significantly improved survival and better-preserved quality of life. Its integration into clinical practice could enhance risk stratification and facilitate personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.